Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has issued an update.
Mayne Pharma Group has notified the market that 100,543 performance rights have lapsed after the conditions attached to those rights were not satisfied by the 30 December 2025 deadline. The cessation of these securities reduces the company’s potential future share issuance under its incentive arrangements and may slightly lessen prospective dilution for existing shareholders, while also indicating that certain performance hurdles or targets tied to management or employee incentives were not met.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company listed on the ASX under the code MYX. The company develops, manufactures and markets branded and generic pharmaceutical products, with a focus on complex and niche therapies for domestic and international markets.
Average Trading Volume: 569,690
Technical Sentiment Signal: Sell
Current Market Cap: A$259.2M
See more data about MYX stock on TipRanks’ Stock Analysis page.